| NCT07172516 | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | RECRUITING | PHASE3 | 2025-08-08 | 2028-08 | 2028-06 |
| NCT07076407 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | RECRUITING | PHASE3 | 2025-07-08 | 2027-07 | 2027-05 |
| NCT06922110 | An Open-Label Study of Azetukalner in Major Depressive Disorder | ENROLLING_BY_INVITATION | PHASE3 | 2025-03-18 | 2027-03 | 2027-01 |
| NCT06775379 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | RECRUITING | PHASE3 | 2024-12-20 | 2026-10 | 2026-08 |
| NCT05716100 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | RECRUITING | PHASE3 | 2023-05-09 | 2025-12 | 2025-08 |
| NCT05718817 | An Open-label Study of XEN1101 in Epilepsy | ENROLLING_BY_INVITATION | PHASE3 | 2023-04-25 | 2028-09 | 2028-07 |
| NCT05667142 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | RECRUITING | PHASE3 | 2023-02-14 | 2027-06 | 2027-04 |
| NCT05614063 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-11-18 | 2026-02 | 2025-12 |
| NCT05376150 | A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder | COMPLETED | PHASE2 | 2022-05-19 | 2023-10-16 | 2023-09-18 |
| NCT04912856 | An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE | TERMINATED | PHASE3 | 2021-08-17 | 2023-11-17 | 2023-11-17 |
| NCT04952467 | Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101 | COMPLETED | PHASE1 | 2021-07-14 | 2021-10-04 | 2021-10-04 |
| NCT04639310 | XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy | TERMINATED | PHASE3 | 2021-03-29 | 2023-05-16 | 2023-05-16 |
| NCT03796962 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-01-30 | 2028-10 | 2021-09-02 |
| NCT03467100 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 | COMPLETED | PHASE1 | 2018-02-19 | 2018-12-19 | 2018-12-19 |
| NCT03468725 | Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101 | COMPLETED | PHASE1 | 2018-02-13 | 2018-07-31 | 2018-07-31 |
| NCT03340220 | Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101. | COMPLETED | PHASE1 | 2017-11-13 | 2021-11-26 | 2021-11-26 |
| NCT02656043 | A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel | COMPLETED | PHASE1, PHASE2 | 2015-09-17 | 2017-03-17 | 2017-02-16 |
| NCT01486446 | Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia | COMPLETED | PHASE1, PHASE2 | 2011-12 | 2012-05 | 2012-04 |
| NCT01195636 | A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) | COMPLETED | PHASE2 | 2010-08 | 2011-03 | 2011-03 |
| NCT01090622 | Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM) | COMPLETED | PHASE1, PHASE2 | 2010-04 | 2010-09 | 2010-08 |
| NCT00954356 | Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction | COMPLETED | PHASE2 | 2009-09 | 2009-12 | 2009-11 |
| NCT00813670 | Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers | COMPLETED | PHASE1 | 2008-11 | 2009-07 | 2009-05 |